Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial

美波利祖马布 医学 哮喘 安慰剂 生活质量(医疗保健) 物理疗法 内科学 随机对照试验 临床终点 儿科 嗜酸性粒细胞 替代医学 病理 护理部
作者
Geoffrey Chupp,Eric Bradford,Frank C. Albers,Daniel J. Bratton,Jie Wang‐Jairaj,Linda Nelsen,Jennifer Trevor,A. Magnan,Anneke Ten Brinke
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:5 (5): 390-400 被引量:584
标识
DOI:10.1016/s2213-2600(17)30125-x
摘要

Background Mepolizumab, an anti-interleukin-5 monoclonal antibody approved as add-on therapy to standard of care for patients with severe eosinophilic asthma, has been shown in previous studies to reduce exacerbations and dependency on oral corticosteroids compared with placebo. We aimed to further assess mepolizumab in patients with severe eosinophilic asthma by examining its effect on health-related quality of life (HRQOL). Methods We did a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial (MUSCA) in 146 hospitals or research centres in 19 countries worldwide. Eligible participants were patients aged 12 years or older with severe eosinophilic asthma and a history of at least two exacerbations requiring treatment in the previous 12 months before screening despite regular use of high-dose inhaled corticosteroids plus other controller medicines. Exclusion criteria included current smokers or former smokers with a history of at least ten pack-years. We randomly assigned participants (1:1) by country to receive a subcutaneous injection of either mepolizumab 100 mg or placebo, plus standard of care, every 4 weeks for 24 weeks (the final dose was given at week 20). We did the randomisation using an interactive voice response system and a centralised, computer-generated, permuted-block design of block size six. The two treatments were identical in appearance and administered in a masked manner; patients, investigators, other site staff and the entire study team including those assessing outcomes data were also masked to group assignment. The primary endpoint was the mean change from baseline in the St George's Respiratory Questionnaire (SGRQ) total score at week 24 in the modified intention-to-treat (modified ITT) population (analysed according to their randomly assigned treatment). Safety was assessed in all patients who received at least one dose of trial medication (analysed according to the actual treatment received). This trial is registered with ClinicalTrials.gov, number NCT02281318. Findings We recruited patients between Dec 11, 2014, and Nov 20, 2015, and the study was undertaken between Dec 11, 2014, and June 10, 2016. The modified ITT population comprised 274 patients assigned to mepolizumab 100 mg and 277 assigned to placebo. Mepolizumab versus placebo showed significant improvements at week 24 from baseline in SGRQ total score (least squares mean [SE] change from baseline −15·6 (1·0) vs −7·9 (1·0), a treatment difference of −7·7 (95% CI −10·5 to −4·9; p<0·0001). No deaths occurred during the study. 192 (70%) of 273 patients who received mepolizumab and 207 (74%) of 278 who received placebo reported at least one on-treatment adverse event, the most common of which were headache (in 45 [16%] given mepolizumab vs 59 [21%] given placebo) and nasopharyngitis (in 31 [11%] given mepolizumab vs 46 [17%] given placebo). 15 (5%) and 22 (8%) patients had an on-treatment serious adverse event in the mepolizumab and placebo groups, respectively; the most common was asthma in both groups (in three [1%] given mepolizumab vs nine [3%] given placebo). Interpretation Mepolizumab was associated with significant improvements in HRQOL in patients with severe eosinophilic asthma, and had a safety profile similar to that of placebo. These results add to and support the use of mepolizumab as a favourable add-on treatment option to standard of care in patients with severe eosinophilic asthma. Funding GlaxoSmithKline.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
Jasper的应助被fortuna采纳,获得10
刚刚
CodeCraft的应助被Charison采纳,获得10
刚刚
Bai完成签到,获得积分10
刚刚
ding的应助被yemiao采纳,获得10
刚刚
1秒前
活力的姆总监完成签到,获得积分10
1秒前
2024发布了新的文献求助30
1秒前
皇帝新衣完成签到,获得积分10
1秒前
无私万仇12完成签到,获得积分10
2秒前
ash的应助被清秀的向松采纳,获得10
2秒前
2秒前
呆呆发布了新的文献求助30
3秒前
NexusExplorer的应助被xixi采纳,获得10
3秒前
3秒前
3秒前
3秒前
清i晨发布了新的文献求助20
4秒前
4秒前
七七发布了新的文献求助10
4秒前
5秒前
空新人完成签到,获得积分10
5秒前
5秒前
5秒前
Lilililili完成签到,获得积分10
5秒前
6秒前
细心的雨竹完成签到,获得积分10
6秒前
yaopr完成签到,获得积分10
6秒前
一元完成签到,获得积分10
6秒前
wsd完成签到,获得积分20
6秒前
龙彦完成签到,获得积分10
6秒前
宫野珏发布了新的文献求助10
6秒前
liwei发布了新的文献求助10
7秒前
wanci的应助被九黎采纳,获得10
7秒前
完美世界的应助被Willing采纳,获得10
8秒前
8秒前
hh发布了新的文献求助10
8秒前
mashibeo发布了新的文献求助10
8秒前
mythepsy92完成签到,获得积分10
8秒前
达不溜人发布了新的文献求助10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8161749
求助须知:如何正确求助?哪些是违规求助? 9556240
关于积分的说明 21733360
捐赠科研通 7751657
什么是DOI,文献DOI怎么找? 3427566
关于科研通互助平台的介绍 2552632
邀请新用户注册赠送积分活动 2472047